Skip to main content
FQHC Talent

Cookie notice

Allow detailed analytics to improve the site?It's from us, Google and Vercel, and stays off until you accept. If you're signed in, it can link your visits across devices. Declining doesn't limit what you can use. Details & privacy.

Back to the news

8th Circuit rejects Novartis bid to block Missouri's 340B contract pharmacy law

Federal

Issue

On July 1, 2026, the 8th Circuit upheld the denial of Novartis's bid to block Missouri's SB 751, which requires drugmakers to deliver 340B drugs to all contract pharmacies serving Missouri covered entities. The court found Novartis unlikely to win, and the case returns to the district court.

The Missouri Primary Care Association intervened to defend it.

Key points

  • The 8th Circuit affirmed the denial of Novartis's preliminary injunction against Missouri S.B. 751, finding its extraterritorial effect negligible and nondiscriminatory and declining to revisit preemption.
  • The Missouri Primary Care Association, the state's FQHC association, intervened to defend the law.
  • The case returns to the district court on the merits; multi-state FQHC networks should keep tracking contract-pharmacy protection by judicial circuit.

Part of

Sources for your board packet

This story's source plus 4 related stories and their sources, ready to print for your team or board.

Free. Unlocking the packet subscribes you to Intel Brief. You'll also get a short welcome series and the occasional product update. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.

More in Legislation

Cite this analysis

FQHC Talent. (2026, July 1). 8th Circuit rejects Novartis bid to block Missouri's 340B contract pharmacy law. Source: Missouri Hospital Association; Powers Law (intervenors' counsel). Retrieved November 11, 2026, from https://www.fqhctalent.com/intel/8th-circuit-missouri-sb751-340b-novartis-july-2026